5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial

Category Primary study
JournalBreast
Year 2021
This article has no abstract
Epistemonikos ID: 562923580ed813f9fbad8be88ce7ce70b89f0b3d
First added on: Feb 13, 2025